On January 13, 2025, Kerna Laboratories Inc, a San Francisco-based AI biotech start-up, emerged from stealth with the launch of an AI platform for developing novel RNA-based medicines. Additionally, Kerna Labs closed an oversubscribed seed funding round, with investors including Gradient, Humba Ventures, Tau Ventures, Pioneer Fund, Focalpoint Partners, and prominent angel investors. Wilson Sonsini Goodrich & Rosati advised Kerna Labs on the funding round.

With the launch of its AI platform, the company can tackle critical mRNA design and delivery challenges and aims to unlock the full potential of mRNA as a universal toolkit for genetic medicine.

The Wilson Sonsini team that advised Kerna Labs on the transaction included Jonathan Chan, Peter Bratton, Lindsey Berger, and Laura Odujinrin.

For more information, please see Kerna Labs’ press release.